Clinical Trial Update: A Phase III Study of 2nd-line XELIRI ± Bevacizumab vs. FOLFIRI ± Bevacizumab in mCRC [Phase 3]

View source ↗

Summary

Phase III trial comparing second-line XELIRI +/- bevacizumab to FOLFIRI +/- bevacizumab in metastatic colorectal cancer has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Colorectal Neoplasms
• Digestive System Neoplasms
• Gastrointestinal Neoplasms
• Intestinal Neoplasms
• Neoplasm Metastasis

Drugs mentioned

• Bevacizumab (bevacizumab)
• FOLFIRI (irinotecan, leucovorin, 5-fluorouracil)
• XELIRI

Snippet

Sponsor: Epidemiological and Clinical Research Information Network | Conditions: Colorectal Neoplasms, Neoplasm Metastasis | Phase 3 | Status: COMPLETED